Foghorn Therapeutics elects Dr. Thomas J. Lynch Jr. to Board of Directors

Foghorn Therapeutics Inc.

Dr. Lynch appointed as Class I Director with term ending at 2024 annual meeting.
Received option to purchase 32,000 shares vesting equally over three years.
Appointed to the Science Committee of the Board.
Compensation per non-employee director policy; indemnification agreement to be entered.
No material transactions or arrangements with Dr. Lynch.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Thomas J. Lynch Jr., MD

Class I Director

FHTX · Foghorn Therapeutics Inc.

Effective: 2022-10-27
Filed: October 27, 2022, 7:59 PM ET

On October 27, 2022, the Board of Directors (the “Board”) of Foghorn Therapeutics Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee, elected Thomas J. Lynch Jr., MD to the Board as a Class I Director with a term to expire at the 2024 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas J. Lynch Jr., MD was elected as Class I Director at Foghorn Therapeutics Inc..

Action: elected
Role: Class I Director

Exact text from the filing

On October 27, 2022, the Board of Directors (the “Board”) of Foghorn Therapeutics Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee, elected Thomas J. Lynch Jr., MD to the Board as a Class I Director with a term to expire at the 2024 annual meeting of stockholders.

View on SEC.gov

Foghorn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-027147

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.